> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves GSK Jemperli for Some Endometrial Cancers
- URL: https://www.fdaweb.com/fda-approves-gsk-jemperli-for-some-endometrial-cancers/
- Published: 2021-04-22T12:00:00.000Z
- Updated: 2026-09-14T16:55:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149170

FDA has granted accelerated approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR as determined by an FDA-approved test. An agency [notice](https://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-endometrial-cancer-specific-biomarker?ref=fdaweb.com) says Jemperli works by targeting the cellular pathway known as PD-1/PD-L1\. It helps the body’s immune system in its fight against cancer cells by blocking the pathway, FDA says.

The drug’s safety and efficacy were studied in a single-arm, multi-center trial of 71 patients with dMMR recurrent or advanced endometrial cancer. In the trial, the notice says, 42.3% had a complete response (disappearance of tumor) or a partial response (shrinkage of tumor) in treatment with Jemperli. The response lasted six months or more in 93% of responders.

The drug received priority review and breakthrough therapy designations for this indication.